Podcasts about vivio health

Pramod John, CEO of VIVIO Health, discusses issues with drug pricing and competition in the pharmaceutical industry. He talks about how the current system incentivizes higher spending on healthcare rather than better outcomes, and how lack of transparency and access to data prevents true competition. [00:00:15] Introduces VIVIO Health mission [00:02:07] Background and improving healthcare [00:05:40] US overspends on drugs [00:08:39] Public benefit corporation [00:12:11] Rebates misalign incentives [00:17:29] FDA approves ineffective drugs [00:24:15] FDA efficacy vs. effectiveness [00:29:47] Health insurance exchanges [00:33:03] Humira lacks competition [00:40:51] Lower cost Humira biosimilars [00:44:38] Employers overpay despite alternatives [00:47:53] Consultants have misaligned incentives [00:51:46] Importance of fiduciary duty [00:53:39] Data access drives competition [00:55:33] Similar issues in other industries [00:57:31] Ask doctors for data on treatments Learn more: https://www.viviohealth.com The Business of Pharmacy Podcast™ offers in-depth, candid conversations with pharmacy business leaders. Hosted by pharmacist Mike Koelzer, each episode covers new topics relevant to pharmacists and pharmacy owners. Listen to a new episode every Monday morning.

As a country, we spend approximately $500 billion on prescription drugs. Specialty drugs account for less than 2% of prescriptions but will cost us over $250 billion (that's in 2021)—so, 2% of prescriptions but half the spend. Specialty is the fastest-growing segment of healthcare spend and is a dominant issue that self-funded employers and other purchasers face. But let's dig into that $250 billion being spent on specialty drugs, shall we? I have to say, personally, that if we spent $250 billion but saved more than that in medical costs or if the patient quality of life went up measurably or if life expectancy or overall survival or whatever metric you used to assess quality … if that big spend produced even bigger returns/results, I for one would be like, “OK, trade-offs. Let's discuss.” But the thing is, clinical trials and real-world evidence alike suggest that there's a lot of patients who don't really benefit from the expensive drugs that they are taking or were prescribed, and even those who benefit might not get the results that they're hoping for or even de minimis expecting. In this healthcare podcast, I am talking with Pramod John, CEO of VIVIO Health; and he makes a couple of great points about all of this that I'll repeat here and then he's gonna say them again later in this episode but in context—and probably better. There was some research done that showed for a really popular, really expensive drug, only 2% of patients who took it got the expected, maybe promised, benefits. But 100% of the patients who took that drug got bad, in some cases dangerously bad, diarrhea. This situation is really kind of typical. A drug will work great for some people, mediocre for other people/patients, and not at all for, say, the remaining what might be majority of patients. So, you'll have 2 patients where the results are out of the park, 23 patients where results are pretty darn good, 25 patients reporting meh results but something you can actually still point to, and then maybe 50 patients who see absolutely no improvement in anything. So, here's an important point: Maybe there's, let's just say, 3 drugs or 10 drugs in this therapeutic category, and that same patient distribution is true for all of them—except different drugs may work for different people. So, by enabling access to all the drugs, you can see that patients have a better chance of being in one of those first groups where they actually get results because there's more drugs that they can try and different drugs work differently in different people. But now, let's consider the way that we pay for specialty drugs: One or two of them get on formulary typically, and then all the others are excluded. That said, the purchaser, patient, and/or taxpayer is gonna pay a whole lot of money for those drugs regardless of how well they do or do not work. And with fewer drugs on formulary, there's less of a chance that results gold will be struck. But we're gonna pay a whole lot of money, also in terms of human life, to deal with the direct and cascading side effects of drugs whether they do or don't work. I have to admit, I kind of have a new appreciation for so-called me-too drugs after this conversation. Let me just add that here for the record. My guest today and next week is Pramod John, who is the founder and CEO over at VIVIO Health. VIVIO contracts with self-insured employers and helps their employees/members/patients (whatever you call them) get the right drug. They actually expand access, and the employer saves money. After what I just said, you might be cottoning on to why. The show this week concerns the reality of specialty drugs and what the terms efficacy and effectiveness really mean because they might not mean what you think they mean. As inconceivable as that might feel, I learned something. You might, too. And there are implications—big implications—for all of this for patients/members/employees. Or you and your family. In this episode, we also define and discuss the terms NNT (number needed to treat) and NNH (number needed to harm), which are really important and, in my humble opinion, do not get discussed enough—especially with patients who need to know these things to make informed choices. Next week's show is also with Pramod John, and we get into how what we talk about here intersects with rebates and formularies. Come back for that. It's probably a 400-level class in specialty pharmacy rebating, but some of you will appreciate it. You can learn more at viviohealth.com or by emailing Pramod at pramod@viviohealth.com.   Pramod John, PhD, is the team leader of VIVIO, a public benefit corporation whose mission is to ensure that drugs work in the real world for the people on them and that their costs reflect the value provided. VIVIO's model has improved health outcomes and generated 35% to 40% savings on drug acquisition costs. It accomplishes this by answering three simple questions: (1) Is this the right drug? (2) Is it a fair price? and (3) Is it working for the patient? Before VIVIO, Pramod was founder of Oration PBC (acquired by PokitDok), which gave consumers control over their drug purchasing by capturing the prescription in the physician's office and providing real-time pricing options and automatic routing capabilities. Pramod was also vice president of strategy and innovation at McKesson, the world's largest healthcare company. At McKesson, Pramod helped develop solutions that leveraged advanced technologies and business process improvements to optimize healthcare delivery systems, infrastructure, and supply chains. Earlier, Pramod founded and served as CEO of PacketMotion, Inc, a venture-funded startup in the enterprise network information and policy management industry. VMware later acquired the company. In addition, Pramod founded netExaminer.com, a managed-vulnerability assessment company acquired by SonicWALL. Pramod earned his PhD in electrical engineering from the University of Illinois at Urbana-Champaign. He serves on the board of Wycliffe USA. He also serves on the advisory board of Folia Water and as a mentor at StartX. 05:34 What does a good response mean in pharmaceutical products? 06:06 “Different people get different utility out of something.” 06:31 Why doesn't efficacy mean what you think it means in terms of pharmaceutical products? 08:40 What is the difference between efficacy and effectiveness in Pharma? 09:10 Why aren't drugs' major side effects factored into a drug's efficacy and effectiveness? 10:14 “What's the benefit of this versus what's the harm in this?” 13:35 “Clearly as consumers, we all feel that we're special. But what about physicians?” 14:14 “The benefit itself—what does it have to be?” 15:18 EP334 with Sunita Desai, PhD.17:11 “We tend to think of things as a binary distribution—it works or it doesn't.” 18:22 “The default choice that we start with is often the wrong one.” 20:54 “It doesn't matter why if we can't fix the reason.” 22:02 “At some point, the question becomes, ‘Do we have any information?'” 22:36 Why do other developed countries pay less for their drugs? 24:21 How do we end up with crappy drugs on the market that don't really move the dial? 25:57 EP303 with Anna Kaltenboeck. 27:22 “We can build a better system. And that's what we do every day.” You can learn more at viviohealth.com or by emailing Pramod at pramod@viviohealth.com.   Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs What does a good response mean in pharmaceutical products? Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs “Different people get different utility out of something.” Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs Why doesn't efficacy mean what you think it means in terms of pharmaceutical products? Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs What is the difference between efficacy and effectiveness in Pharma? Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs Why aren't drugs' major side effects factored into a drug's efficacy and effectiveness? Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs “What's the benefit of this versus what's the harm in this?” Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs “Clearly as consumers, we all feel that we're special. But what about physicians?” Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs “The benefit itself—what does it have to be?” Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs “We tend to think of things as a binary distribution—it works or it doesn't.” Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs “The default choice that we start with is often the wrong one.” Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs “It doesn't matter why if we can't fix the reason.” Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs “At some point, the question becomes, ‘Do we have any information?'” Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs Why do other developed countries pay less for their drugs? Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs How do we end up with crappy drugs on the market that don't really move the dial? Pramod John discusses #specialtydrugpricing on our #healthcarepodcast. #healthcare #podcast #pharma #specialtypharma #specialtydrugs   Recent past interviews: Click a guest's name for their latest RHV episode! Dr Eric Bricker, Katy Talento, Stacey Richter (INBW33), Stacey Richter (INBW32), Dr Steve Schutzer (Encore! EP294), Lisa Trumble, Jeb Dunkelberger, Dr Ian Tong, Mike Schneider, Peter Hayes, Paul Simms, Dr Steven Quimby, Dr David Carmouche (EP343), Christin Deacon, Gary Campbell, Kristin Begley, David Contorno (AEE17), David Contorno (EP339), Nikki King, Olivia Webb, Brandon Weber, Stacey Richter (INBW30), Brian Klepper (AEE16), Brian Klepper (EP335), Sunita Desai, Care Plans vs Real World (EP333), Dr Tony DiGioia, Al Lewis

S1E9: Healthcare's Asymmetry of Information with Pramod John, CEO of Vivio Health, and host Dr. Nick. Do you know if the drugs you are prescribed and are taking are actually delivering value? Who has your best interests front and center and you trust to make a determination and guide the clinical decision-making process on what therapy is indicated for the disease in you? If you were leaning on the FDA, recent news and events might give you pause. Recently conditionally approved Aduhelm an Alzheimer treatment by Biogen is controversial and pricey. Medicare premiums at all time high in part from the impact of Aduhelm. So what about the information and data available, the science? Drug pricing is outstripping our ability to pay, and a large portion of these escalating costs is linked to specialty drugs that can account for as much as 50% of costs while only treating a small percentage of patients. Your better pill to swallow, we can no longer accept the value of a treatment based on it being prescribed and our assumption that all the processes in place make this choice the right choice for you since the assumptions are not aligned with yours and in fact may be counter. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play HealthcareNOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Driven by a personal passion to change healthcare and “the obligation to do the right thing for the good of every American,” Pramod John, CEO of Vivio Health, is on a mission to overhaul the specialty drug market. He and the team at Vivio - founded by a leaders previously working in Pharma - want to use data to help people get the right drug, at the right time.  Pramod says medications are the most frequent intervention a physician will make, and that specialty drugs are the fastest growing segment of healthcare globally.  Yet, he also says that many of the drugs aren't widely effective.  The team of Vivio sees opportunity for change and is working to improve things by using and analyzing real-world drug and patient data - analyzed separately from the FDA. Learn more about Vivio Health: https://viviohealth.com  Connect with Pramod: https://www.linkedin.com/in/pramod-john/  Topical time codes: 00:00 - Video starts 00:58 - Creation of Vivio Health 2:28 - Specialty drug market 5:15 - Endorsement of specialty drugs by influencers and celebs 8:04 - Lack of time to analyze drug trial info of every new drug 12:08 - Too much info for physicians to keep up with in practice, no infrastructure to help  14:56 - Using computers to keep up with data doesn't mean human replacement - they're good at different things  17:26 - Switch in thinking to allow change and let people work at their highest level 20:56 - Using technology more often and using it better 23:36 - Personal passion for change

This episode of The ShiftShapers Podcast is called "Target and Tame the Drug Spend Monster" with Pramod John, Founder and CEO at VIVIO Health. They discuss the changing nature of specialty drugs as adjuvant therapies and the skyrocketing costs that come with it. Pramod also discusses the case of Humira biosimilars and AbbVie's threat to litigate, resulting in it being unavailable in the US. He further explains the broken system that favors big pharma, its detrimental effect on regular citizens, and what we can do about it. You can find show notes and more information by clicking here: https://bit.ly/2ALItrX

Topics: Pharmacy Benefit Manager (PBM) Misaligned Incentives Price Transparency  Efficacy versus Effectiveness Consumerism Specialty Drugs Drug Waste Drug Manufacturer Rebate Steerage   In this episode, Michael introduces you to Mort Jorgensen, the Co-founder, and CEO of Rx’n Go, Paul Ford, the Founder of OrchestraRx and Pramod John, the CEO of VIVIO Health. Join our round table as we dive into the current state of the Pharmacy Marketplace and ideas to challenge the inefficiencies and problems in traditional Rx purchasing.  Here’s a glance at what we discuss in this episode: The table’s opinion about the current mergers of the largest PBMs with insurance companies and how this could impact the marketplace The complexities and challenges with the current pharmacy purchasing structure  How payors have zero visibility into the pricing for Generics, Brand and Specialty Drugs How current benefit design is a part of the transparency problem  The Pareto Principle, how it relates to drug spend and why employers need to take a more proactive stance on what drugs are allowed to be used if they want to save money How the presence of multiple middlemen in the drug distribution system creates additional cost and inefficiency Why our biggest problem may not be a lack of transparency, but rather an unwillingness for payors to stop doing business with the vendors who profit off of higher drug costs Misconceptions about drug manufacturer rebates and why the impact of rebate driven drug steerage should be a greater concern than how much the drugs cost Understanding which stakeholders benefit from drug manufacturer rebates  Understanding that consumerism doesn’t really work when it comes to drug choice given it is usually a provider who is the one selecting the drug for the patient The differences between efficacy versus effectiveness and why we continue to pay for drugs that do not work How employers can reduce waste within their benefit design How employers can protect themselves from Big Pharma and Specialty Drug costs Why FDA approval of a drug doesn’t necessarily warrant covering it on an employer’s formulary Why paying for bad drugs that don’t work creates a disincentive for Pharma to create drugs that actually work Why employers need to start taking a more proactive role in selecting what drugs they are willing to cover and pay for Questions that an employer should be asking to ensure their pharmacy vendors have aligned incentives  The government’s role in creating policies that address data sharing, drug pricing, and transparency To learn more about Rx’n Go visit: (https://www.rxngo.com/) To learn more about OrchestraRx visit: (https://www.orchestrarx.com/) To learn more about VIVIO Health visit: (https://viviohealth.com/)

Podcast Show Notes Our podcast discussion today between Michael Andrade and  Pramod John, CEO of Vivio Health.  We discuss what Vivio Health does to deliver Precision Care in specialty medication compliance versus the traditional prior authorization process.  You may be surprised to learn some things that are contrary [...]

Specialty drugs represent an ever-growing driver of our overall enormous drug spend. Pramod John, our guest on this episode, is CEO of Vivio Health, which is singularly focused on using outcomes revealed by data and analytics to bend the hockey-stick curve of this spending trend. You can find show notes and more information by clicking here: http://bit.ly/2RJwTQL  

Topics: Specialty Drugs Data Analytics Net Acquisition Cost vs. Discount Pricing Improving Health Outcomes Specialty Drug Waste Prior Authorization Cost Savings Misaligned Incentives In this episode, Michael introduces you to Pramod John, CEO of VIVIO Health. Join us as we discuss how VIVIO Health, a specialty drug platform, utilizes data analytics and outcomes based models to help employers control their specialty drug spend. Here’s a glance at what we discuss in this episode: Pramod John’s software engineering and supply chain background and why he founded VIVIO Health How drugs may be prescribed off-label and physicians prescribing patterns may be influenced by payments from drug manufacturers How misaligned incentives have propelled our healthcare system into a cycle of complacency and how VIVIO Health seeks to break the cycle Why its critical to focus on specialty drugs to contain costs in Rx spending Why the current discount pricing model doesn’t work and leads to higher medical inflation year after year Why a focus on specialty drug discount guarantees in PBM contracts may not be in the best interest of employers and lead to the purchase of higher cost drugs when lower cost drugs are available Why the assumption that smaller companies like VIVIO Health can’t negotiate pricing competitive with Big PBM’s is false Why a stamp of approval from the FDA may not mean a drug is safe or effective The difference between effectiveness of a drug and efficacy and how many drugs on formularies are not impactful for improving clinical conditions they are designed to treat The problems with the traditional prior authorization process and how VIVIO Health has  changed the process to be a data driven approach to determining the optimal therapy for the specific patient How VIVIO Health’s data collection process helps an employer to monitor if the drugs that are being prescribed are actually working and effective The resistance from PBM’s to allow a vendor like VIVIO Health to carve out the administration, procurement and management of the specialty drug component VIVIO Health’s platform and how they are improving the employee experience and helping reduce waste in prescribing practices and employer spend on specialty drugs by 30% to 50% VIVIO Health’s transparent cost structure and typical ROI with current clients Obstacles that VIVIO Health has overcome to implementing their program with employers VIVIO Health’s website and contact information: (http://www.viviohealth.com/) , pramod@viviohealth.com

Pramod John is team leader of Vivio Health, a company that is reinventing the therapeutic use and supply chain for the specialty drug space. The Vivio Health plan solution is challenging the current framework of efficacy and extending it to true effectiveness in the real world. It also offers significant drug acquisition savings and simplicity for the patient by integrating the supply chain into a unified and data driven process. Prior to Vivio Health, Pramod was founder of Oration PBC (acquired by PokitDok) which was focused on giving back consumers control over their drug purchasing by capturing the prescription in the physician's office and providing real-time pricing options and automatic routing capabilities. Pramod was also VP of Strategy and Innovation at McKesson, the world's largest health care company. At McKesson, Pramod helped develop solutions that leveraged advanced technologies and business process improvements to optimize health care delivery systems, infrastructure, and supply chains. Earlier, Pramod founded and served as CEO of PacketMotion, Inc., a venture-funded startup in the enterprise network information and policy management industry. The company was later acquired by VMware. In addition, Pramod founded netExaminer.com, a managed-vulnerability assessment company acquired by SonicWALL (owned by Dell). Pramod earned his PhD in Electrical Engineering from the University of Illinois at Urbana-Champaign. He serves on the Boards of Mission Aviation Fellowship, a global relief organization, and 3Crosses Church in Castro Valley, CA. He also serves on the advisory board of Folia Water and as a mentor at StartX. 00:00 What aspects of health care that Vivio solves. 02:15 What would care look like by starting with the question, “What outcome do we want to see?” 04:40 Benefit designs. 06:00 Vivio's customers. 06:50 How this works from the patient side. 09:00 How this looks from a clinician standpoint. 13:00 Proactively building clinical models and data collection. 13:30 Results of Vivio's transparency. 14:45 How this comes down to a numbers problem. 15:00 “There's very little clinical to do in a clinical trial.” 17:00 The types of reports that Vivio comes up with, and who they benefit? 19:00 “How do we help people see, ‘Here are the one or two things you need to understand.” 22:30 You can learn more at www.viviohealth.com.

Pramod John is team leader of VIVIO Health, a company that is reinventing the therapeutic use and supply chain for the specialty drug space. VIVIO Health's solution is challenging the current framework of efficacy and extending it to true effectiveness in the real world. It also offers significant drug acquisition savings and simplicity for the patient by integrating the supply chain into a unified and data driven process. Prior to VIVIO Health, Pramod was founder of Oration PBC (acquired by Pokitdok) which was focused on giving back consumers control over their drug purchasing by capturing the prescription in the physician's office and providing real time pricing options and automatic routing capabilities.   Pramod was also VP of Strategy and Innovation at McKesson, the world's largest healthcare company. At McKesson, Pramod helped develop solutions that leveraged advanced technologies and business process improvements to optimize healthcare delivery systems, infrastructure and supply chains. Earlier, Pramod founded and served as CEO of PacketMotion, Inc., a venture-funded startup in the enterprise network information and policy management industry. The company was later acquired by VMWare. In addition, Pramod founded netExaminer.com, a managed-vulnerability assessment company acquired by SonicWALL (owned by Dell). Pramod earned his Ph.D. in Electrical Engineering from the University of Illinois at Urbana-Champaign. He serves on the Boards of Mission Aviation Fellowship, a global relief organization and 3 Crosses Church in Castro Valley, CA. He also serves on the advisory board of Folia Water and as a mentor at StartX. 00:00 Pramod's article on Amazon getting into Pharmacy & Stacey's Inbetweenisode 14. 00:45 The four key structural roadblocks Amazon would have to overcome to get into Pharmacy. 02:20 The issues in the pharmacy space & the hope that a disruptor can come in and fix these issues. 03:50 What Amazon would have to do to overcome the current issues in the drug market. 05:00 What innovation would Amazon have to bring to the market to truly be innovative? 07:00 The unmovable vested interests in the pharma industry. 08:15 The monopoly of the pharma industry on the micro level. 09:45 Why consumers go to Amazon. 10:15 The difference between the health care consumer market and other consumer markets. 11:10 The primary driver for consumers in the drug space. 12:20 The disjointed process of prescriptions and pharmacies. 13:15 What will lead to real disruption in this industry. 15:15 “Amazon doesn't just mean Amazon anymore.” 16:15 The difference Amazon has made in an unregulated market versus a regulated market. 17:00 “What are we going to do about these intermediaries?” 17:30 The economic problem in the pharma market. 17:45 The best strategy to completely change the dynamics of the industry. 18:10 Taking insurance, Getting in Network, E-Prescribing, Buying a PBM. 22:45 “You can't grow demand when three people control 70% of the market.” 28:50 The self-administered space. 30:15 “Disruption is going to come because we're getting ahead of where the money is coming from in the future.” 31:00 You can learn more at www.viviohealth.com.

Pramod John, CEO/Founder of Vivio Health is on All Business this week. Prior to VIVIO Health, Pramod was the founder of Oration PBC which is changing the way consumers purchase prescription medications by capturing the prescription in the physician’s office and providing all the pricing options and routing automatically. This episode is sponsored by Dunkin’ Donuts and Liberty Tax. Learn more about your ad choices. Visit megaphone.fm/adchoices

A fantastic episode of America's Healthcare Challenge.. Are receiving a premium increase on your insurance? Chances are skyrocketing drug costs are a major reason. On America's Healthcare Challenge, the CEO of Vivio Health, joins to talk about how they are cracking the supply side code of the pharmaceutical industry. For more: www.HealthReformExplained.com

Are you paying more for prescription drugs this year? In this thought provoking segment of America's Healthcare Challenge, the CEO of Vivio Health joins host Sean McGuire and the gang for a conversation on drug prices you do not want to miss. For more check out: www.HealthReformExplained.com

Pramod John who is the CEO of Vivio Health explains the tremendous challenge of specialty drug costs and how the great people at www.viviohealth.com are solving the problem. www.HealthReformExplained.com